Business Description
Surgical Science Sweden AB
ISIN : SE0014428512
Compare
Compare
Traded in other countries / regions
SUS.SwedenSUSRF.USA4P41.Germany IPO Date
2021-04-16Description
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments; Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations, prior to entering the clinical environment and also support and services, and Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments and also simulators for medical device companies.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.65 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 14.16 | |||||
| Beneish M-Score | -2.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 78.5 | |||||
| 3-Year EBITDA Growth Rate | 80.6 | |||||
| 3-Year EPS without NRI Growth Rate | 116.9 | |||||
| 3-Year FCF Growth Rate | 108.1 | |||||
| 3-Year Book Growth Rate | 90.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 20.18 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.65 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.96 | |||||
| 9-Day RSI | 47.35 | |||||
| 14-Day RSI | 52.94 | |||||
| 6-1 Month Momentum % | 14.45 | |||||
| 12-1 Month Momentum % | -15.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.44 | |||||
| Quick Ratio | 3.73 | |||||
| Cash Ratio | 2.73 | |||||
| Days Inventory | 229.22 | |||||
| Days Sales Outstanding | 48.78 | |||||
| Days Payable | 55.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.9 | |||||
| Shareholder Yield % | -0.32 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.65 | |||||
| Operating Margin % | 16.61 | |||||
| Net Margin % | 22.49 | |||||
| FCF Margin % | 8.51 | |||||
| ROE % | 4.3 | |||||
| ROA % | 3.97 | |||||
| ROIC % | 2.77 | |||||
| ROC (Joel Greenblatt) % | 221.28 | |||||
| ROCE % | 4.83 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 40.9 | |||||
| Forward PE Ratio | 31.66 | |||||
| PE Ratio without NRI | 40.9 | |||||
| Price-to-Owner-Earnings | 89.13 | |||||
| PEG Ratio | 0.47 | |||||
| PS Ratio | 9.2 | |||||
| PB Ratio | 1.78 | |||||
| Price-to-Tangible-Book | 9.72 | |||||
| Price-to-Free-Cash-Flow | 108.39 | |||||
| Price-to-Operating-Cash-Flow | 65.82 | |||||
| EV-to-EBIT | 33.15 | |||||
| EV-to-Forward-EBIT | 23.16 | |||||
| EV-to-EBITDA | 33.15 | |||||
| EV-to-Forward-EBITDA | 19.64 | |||||
| EV-to-Revenue | 8.59 | |||||
| EV-to-Forward-Revenue | 6.92 | |||||
| EV-to-FCF | 100.21 | |||||
| Price-to-Projected-FCF | 1.77 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.65 | |||||
| Price-to-Graham-Number | 4.2 | |||||
| Price-to-Net-Current-Asset-Value | 10.9 | |||||
| Price-to-Net-Cash | 25.3 | |||||
| Earnings Yield (Greenblatt) % | 3.01 | |||||
| FCF Yield % | 0.91 | |||||
| Forward Rate of Return (Yacktman) % | 21.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Surgical Science Sweden AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 76.194 | ||
| EPS (TTM) (€) | 0.338 | ||
| Beta | 0.1 | ||
| Volatility % | 29.93 | ||
| 14-Day RSI | 52.94 | ||
| 14-Day ATR (€) | 0.295878 | ||
| 20-Day SMA (€) | 13.5045 | ||
| 12-1 Month Momentum % | -15.73 | ||
| 52-Week Range (€) | 9.745 - 16.96 | ||
| Shares Outstanding (Mil) | 51.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surgical Science Sweden AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surgical Science Sweden AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Surgical Science Sweden AB Frequently Asked Questions
What is Surgical Science Sweden AB(FRA:4P41)'s stock price today?
The current price of FRA:4P41 is €13.41. The 52 week high of FRA:4P41 is €16.96 and 52 week low is €9.74.
When is next earnings date of Surgical Science Sweden AB(FRA:4P41)?
The next earnings date of Surgical Science Sweden AB(FRA:4P41) is 2025-02-19.
Does Surgical Science Sweden AB(FRA:4P41) pay dividends? If so, how much?
Surgical Science Sweden AB(FRA:4P41) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers